NUR612/NUR612 Exam 1 V3 | Advance
Pharmacology Q&A with Rationale |
William Paterson University
1. Which pharmacokinetic process is primarily responsible for the ‘first-pass effect’ observed
with oral medications?
A. Renal excretion
B. Hepatic metabolism
C. Gastric absorption
D. Protein binding
Answer: B
Rationale: The first-pass effect occurs when a drug is metabolized by the liver before
reaching systemic circulation. This process significantly reduces the bioavailability of many
oral medications. Understanding this effect is crucial for determining the appropriate route
and dosage for various drugs.
2. A drug has a half-life of 4 hours. If a patient takes a 100 mg dose, how much of the drug
remains in the body after 12 hours?
A. 50 mg
B. 12.5 mg
C. 25 mg
,D. 6.25 mg
Answer: B
Rationale: After one half-life (4 hours), 50 mg remains; after two half-lives (8 hours), 25
mg remains. After three half-lives (12 hours), 12.5 mg remains in the system. This
calculation helps clinicians understand drug accumulation and clearance rates in clinical
practice.
3. What is the primary difference between a full agonist and a partial agonist?
A. A partial agonist has higher affinity but lower efficacy than a full agonist.
B. Full agonists only bind to intracellular receptors while partial agonists bind to cell
surface receptors.
C. A partial agonist cannot produce the maximal effect regardless of the concentration.
D. Partial agonists act as permanent antagonists in the presence of full agonists.
Answer: C
Rationale: A full agonist can produce the maximum possible response by fully activating
receptors. In contrast, a partial agonist produces a sub-maximal response even when all
receptors are occupied. This concept is vital for understanding how different drugs in the
same class produce varying levels of clinical effect.
4. Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of all
clinically used drugs?
A. CYP2D6
, B. CYP1A2
C. CYP3A4
D. CYP2C19
Answer: C
Rationale: CYP3A4 is the most abundant and significant enzyme in the cytochrome P450
system. It is involved in the metabolism of a vast majority of medications, including statins
and calcium channel blockers. Knowledge of this enzyme is essential for predicting and
preventing potential drug-drug interactions.
5. If a drug is a known ‘inducer’ of a specific CYP450 enzyme, how does it affect a ‘substrate’
drug of that same enzyme?
A. It increases the substrate drug’s serum levels.
B. It causes the substrate drug to become highly protein-bound.
C. It has no effect on the metabolism of the substrate drug.
D. It decreases the substrate drug’s serum levels.
Answer: D
Rationale: Inducers increase the activity and production of metabolic enzymes in the liver.
This leads to faster metabolism of substrate drugs, which results in lower serum
concentrations. Clinicians must often increase the dose of the substrate drug to maintain
therapeutic efficacy in these scenarios.
Pharmacology Q&A with Rationale |
William Paterson University
1. Which pharmacokinetic process is primarily responsible for the ‘first-pass effect’ observed
with oral medications?
A. Renal excretion
B. Hepatic metabolism
C. Gastric absorption
D. Protein binding
Answer: B
Rationale: The first-pass effect occurs when a drug is metabolized by the liver before
reaching systemic circulation. This process significantly reduces the bioavailability of many
oral medications. Understanding this effect is crucial for determining the appropriate route
and dosage for various drugs.
2. A drug has a half-life of 4 hours. If a patient takes a 100 mg dose, how much of the drug
remains in the body after 12 hours?
A. 50 mg
B. 12.5 mg
C. 25 mg
,D. 6.25 mg
Answer: B
Rationale: After one half-life (4 hours), 50 mg remains; after two half-lives (8 hours), 25
mg remains. After three half-lives (12 hours), 12.5 mg remains in the system. This
calculation helps clinicians understand drug accumulation and clearance rates in clinical
practice.
3. What is the primary difference between a full agonist and a partial agonist?
A. A partial agonist has higher affinity but lower efficacy than a full agonist.
B. Full agonists only bind to intracellular receptors while partial agonists bind to cell
surface receptors.
C. A partial agonist cannot produce the maximal effect regardless of the concentration.
D. Partial agonists act as permanent antagonists in the presence of full agonists.
Answer: C
Rationale: A full agonist can produce the maximum possible response by fully activating
receptors. In contrast, a partial agonist produces a sub-maximal response even when all
receptors are occupied. This concept is vital for understanding how different drugs in the
same class produce varying levels of clinical effect.
4. Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of all
clinically used drugs?
A. CYP2D6
, B. CYP1A2
C. CYP3A4
D. CYP2C19
Answer: C
Rationale: CYP3A4 is the most abundant and significant enzyme in the cytochrome P450
system. It is involved in the metabolism of a vast majority of medications, including statins
and calcium channel blockers. Knowledge of this enzyme is essential for predicting and
preventing potential drug-drug interactions.
5. If a drug is a known ‘inducer’ of a specific CYP450 enzyme, how does it affect a ‘substrate’
drug of that same enzyme?
A. It increases the substrate drug’s serum levels.
B. It causes the substrate drug to become highly protein-bound.
C. It has no effect on the metabolism of the substrate drug.
D. It decreases the substrate drug’s serum levels.
Answer: D
Rationale: Inducers increase the activity and production of metabolic enzymes in the liver.
This leads to faster metabolism of substrate drugs, which results in lower serum
concentrations. Clinicians must often increase the dose of the substrate drug to maintain
therapeutic efficacy in these scenarios.
